Navigation Links
Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
Date:9/10/2013

CHARLESTON, S.C., Sept. 10, 2013 /PRNewswire/ -- Plasma Technologies LLC, a plasma biologics technology company, announced the recent issuance of US patent #8,293,242, an "Ultra-High Yield of Alpha-1 Antitrypsin" and the Company's plans to commercialize its patented extraction process for plasma biologics. The Company's technology fundamentally changes the economics of blood plasma fractionation by substantially increasing the yield of alpha-1 antitrypsin (AAT) and intravenous immune globulin (IVIG) and makes possible the extraction of several additional therapeutically useful plasma proteins.  The non-denaturing process will enable plasma-derived biologics to be differentiated on the basis of improved molecular integrity that will enhance patient tolerance, will minimize the danger of thromboembolic events and will preserve the serum half-lives of the biomolecules.

The existing $15 Billion worldwide plasma biologics market is substantially underserved, and continues to grow at about 10% annually. Driving that growth is the demand for AAT, used to treat a growing number of diseases. AAT deficiency is a genetic condition resulting in damage to lung, liver, and pancreatic tissues, with pulmonary emphysema as the most common indication. In North America and Europe there at least 150,000 people living with AAT deficiency, but fewer than 10,000 receive AAT therapy, which is lifelong and involves weekly injections of AAT. Administration of AAT in non-deficient individuals may interfere with disease progression in the following conditions:  Diabetes (type 1 & 2), acute myocardial infarction, inflammatory bowel disease, cystic fibrosis, graft vs. host disease, stroke, Alzheimer's disease, vasculitis, organ transplantation, and multiple sclerosis.

Current methods of AAT production cannot meet the demand created by the expanding number of clinical indications. Plasma Technologies LLC believes that AAT can be supplied in volumes needed to meet current and future demand through the adoption by pharmaceutical manufacturers of the Company's proprietary extraction process, the elements of which are salt precipitation from plasma, subsequent salt removal by diafiltration and final purification by means of affinity and ion exchange chromatography. Increased supply of AAT will be complemented by new low-cost genetic tests that identify patients likely to benefit from AAT therapy.

The Company's process and technology are covered by US Patents #7,879,331, #7,879,332, and #8,293,242, the last of which will not expire until November 2030.  Patents have also been filed in major patent jurisdictions outside the United States.

Additional information about the Company and its technology can be found on its website at www.plasmatechnologies.us


'/>"/>
SOURCE Plasma Technologies LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be Effective in Dilated Cardiomyopathy
2. SoundConnect Recently Selected by iCIMS, Inc.
3. Recently FDA-Approved Full Neck Treatment for Sagging Skin Now Available at Maryland Laser Skin and Vein Institute
4. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
5. DryLet Technologies Announces the Rebranding and Launch of Patented ManureMagic™
6. DryLet Technologies Announces Website Launch and New Logo Design for Patented MB Bioremediation
7. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
8. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
9. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
10. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
11. Netswitch Technology Management Ranks in Top 100 Cloud and Managed Service Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... Charm Sciences, Inc. is pleased to announce the Charm® ROSA® Tetracycline-SL ... Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a drug residue test kit ... NCIMS voted at its annual meeting in April, 2015 to establish a pilot program ...
(Date:7/24/2017)... , July 24, 2017 Intralytix, Inc. announced ... from Lesaffre, a French family group. This investment marks ... to develop and commercialize bacteriophage-based products, for various benefits ... interest. As ... designs manufactures and markets innovative solutions for baking, food ...
(Date:7/24/2017)... ... July 24, 2017 , ... Each year, Inavero’s Best ... proven their superior service quality as rated by hiring professionals and job candidates. ... based on service quality ratings from their placed talent. , Fewer than 2% ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... market news outlet had initiated coverage on Interpace Diagnostics. Interpace Diagnostics is ... exposure, progression and risk analysis from specific cancers in humans. , According ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):